• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VLA
Click for more information
0.00% $1.75

VIRALYTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VLA Appendix 3B-VLA.AX 27/09/16
VLA Ceasing to be a substantial holder-VLA.AX 21/09/16
VLA VLA to Present CAVATAK Clinical Data at Upcoming Conferences-VLA.AX 21/09/16
VLA Date of Annual General Meeting-VLA.AX 19/09/16
VLA Appendix 3B-VLA.AX 15/09/16
VLA Appendix 4G and Corporate Governance Statement-VLA.AX 28/08/16
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX PRICE SENSITIVE28/08/16
VLA Viralytics Annual Report and Full Year Financial Results-VLA.AX 28/08/16
VLA Viralytics Annual Report and Full Year Financial Results-VLA.AX 25/08/16
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX PRICE SENSITIVE25/08/16
VLA Appendix 4G and Corporate Governance Statement-VLA.AX 25/08/16
VLA Change in substantial holding-VLA.AX 29/07/16
VLA Cleansing Notice-VLA.AX 28/07/16
VLA Appendix 3B-VLA.AX 28/07/16
VLA Appendix 4C - quarterly-VLA.AX PRICE SENSITIVE26/07/16
VLA Change of Director's Interest Notice-VLA.AX 29/06/16
VLA Cleansing Notice-VLA.AX 28/06/16
VLA Appendix 3B-VLA.AX 28/06/16
VLA Change in substantial holding-VLA.AX 17/06/16
VLA Updated Clinical Trial Data Presented at ASCO Annual Meeting-VLA.AX PRICE SENSITIVE06/06/16
VLA Cleansing Notice-VLA.AX 26/05/16
VLA Appendix 3B-VLA.AX 26/05/16
VLA Change of Director's Interest Notice-VLA.AX 09/05/16
VLA Viralytics Corporate Presentation May 2016-VLA.AX 04/05/16
VLA Appendix 4C - quarterly-VLA.AX PRICE SENSITIVE28/04/16
VLA Positive Clinical Data from CAVATAK and YERVOY Combination-VLA.AX PRICE SENSITIVE19/04/16
VLA CAVATAK Immune Activity in Tumour Micro-environment-VLA.AX PRICE SENSITIVE19/04/16
VLA Checkpoint Combination active in Preclinical Lung, Melanoma-VLA.AX PRICE SENSITIVE19/04/16
VLA Viralytics to Present Clinical Data at AACR Annual Meeting17/03/16
VLA Positive CAVATAK Clinical Data Presented at EAU CongressPRICE SENSITIVE15/03/16
VLA S&P DJ Indices Announces March Quarterly Review11/03/16
VLA Appendix 4D Half Yearly Report and AccountsPRICE SENSITIVE23/02/16
VLA Change of Director's Interest Notice02/02/16
VLA Appendix 4C - quarterlyPRICE SENSITIVE27/01/16
VLA Appendix 3B - Share Purchase Plan27/01/16
VLA Viralytics Completes $4 Million Share Purchase Plan25/01/16
VLA Ceasing to be a substantial holder04/01/16
VLA Change in substantial holding23/12/15
VLA Change in substantial holding23/12/15
VLA Appendix 3B and Cleansing Notice21/12/15
VLA Becoming a substantial holder21/12/15
VLA Despatch of Share Purchase Plan Offer Documents17/12/15
VLA Viralytics Share Purchase Plan14/12/15
VLA Cleansing Notice - Share Purchase Plan14/12/15
VLA Additional Placement Details14/12/15
VLA Viralytics completes $28 million Placement - SPP to followPRICE SENSITIVE14/12/15
VLA Trading HaltPRICE SENSITIVE10/12/15
VLA Viralytics Receives $2.9 Million R&D Tax IncentivePRICE SENSITIVE09/12/15
VLA Change of Director's Interest Notice x 420/11/15
VLA Appendix 3B18/11/15
VLA Results of Meeting18/11/15
VLA AGM Presentation18/11/15
VLA Chairman's Address to Shareholders18/11/15
VLA Positive CAVATAK Clinical Data Presented at 2015 SITCPRICE SENSITIVE09/11/15
VLA Viralytics and Merck Collaborate in Lung and Bladder CancerPRICE SENSITIVE06/11/15
VLA Appendix 4C - quarterlyPRICE SENSITIVE28/10/15
VLA Notice of Annual General Meeting/Proxy Form19/10/15
VLA Appendix 3B - Issue of Options and Performance Rights28/09/15
VLA VLA initiates Clinical Trial of CAVATAK and PD-1 CombinationPRICE SENSITIVE28/09/15
VLA Viralytics Presents Data at European Cancer CongressPRICE SENSITIVE28/09/15
VLA Date of Annual General Meeting17/09/15
VLA Director and Management Options for Viralytics Leadership15/09/15
VLA Appendix 3B08/09/15
VLA Viralytics Annual Report and Full Year Financial Results26/08/15
VLA Appendix 4G and Corporate Governance Statement26/08/15
VLA Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE26/08/15
VLA Appendix 4C - quarterlyPRICE SENSITIVE21/07/15
VLA Presentation Bioshares Biotech Summit17/07/15
VLA Appendix 3B29/06/15
VLA Revised Securities Trading Policy25/06/15
VLA Becoming a substantial holder23/06/15
VLA VLA presents on CALM and STORM at OV Conference17/06/15
VLA Correction to Announcement - CAVATAK Presentations16/06/15
VLA CAVATAK Presentations Potential in Bladder Cancer & Melanoma16/06/15
VLA Investor Teleconference - CAVATAK CALM Trial Results12/06/15
VLA VLA to Present CAVATAK Bladder and Other Results at Conf.09/06/15
VLA Positive final results from CAVATAK Phase 2 Melanoma TrialPRICE SENSITIVE02/06/15
VLA VLA to present final CALM Clinical Data at ASCO 201513/05/15
VLA Appendix 4C - quarterlyPRICE SENSITIVE28/04/15
VLA AACR Annual Meeting - Update on CALM & STORM TrialsPRICE SENSITIVE21/04/15
VLA Ceasing to be a substantial holder15/04/15
VLA VLA to present CAVATAK clinical data at AACR Annual Meeting18/03/15
VLA Viralytics to Present at Annual ROTH Investment Conference09/03/15
VLA Response to Price Query LetterPRICE SENSITIVE27/02/15
VLA Half Yearly Report and AccountsPRICE SENSITIVE17/02/15
VLA VLA commences Clinical Trial of CAVATAK in Bladder CancerPRICE SENSITIVE27/01/15
VLA Appendix 4C - quarterlyPRICE SENSITIVE22/01/15
VLA Change of Director's Interest Notice04/12/14
VLA Commencement of Checkpoint Inhibitor Combination trialPRICE SENSITIVE04/12/14
VLA Viralytics Receives $2.5 Million R&D Tax IncentivePRICE SENSITIVE02/12/14
VLA Correction - Change of Director's Interest Notice28/11/14
VLA Appendix 3B - Correction28/11/14
VLA Change of Director's Interest Notices28/11/14
VLA Appendix 3B28/11/14
VLA Change in substantial holding28/11/14
VLA Results of Meeting27/11/14
VLA Managing Director's AGM Address27/11/14
VLA Chairman's AGM Address27/11/14
VLA Viralytics Shareholder Newsletter Nov 201424/11/14
VLA Approval for CAVATAK Clinical Trial - Bladder CancerPRICE SENSITIVE14/11/14
VLA Appendix 3B-VLA.AX
27/09/16
VLA Ceasing to be a substantial holder-VLA.AX
21/09/16
VLA VLA to Present CAVATAK Clinical Data at Upcoming Conferences-VLA.AX
21/09/16
VLA Date of Annual General Meeting-VLA.AX
19/09/16
VLA Appendix 3B-VLA.AX
15/09/16
VLA Appendix 4G and Corporate Governance Statement-VLA.AX
28/08/16
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX
28/08/16PRICE SENSITIVE
VLA Viralytics Annual Report and Full Year Financial Results-VLA.AX
28/08/16
VLA Viralytics Annual Report and Full Year Financial Results-VLA.AX
25/08/16
VLA Appendix 4E and Full Year Statutory Accounts-VLA.AX
25/08/16PRICE SENSITIVE
VLA Appendix 4G and Corporate Governance Statement-VLA.AX
25/08/16
VLA Change in substantial holding-VLA.AX
29/07/16
VLA Cleansing Notice-VLA.AX
28/07/16
VLA Appendix 3B-VLA.AX
28/07/16
VLA Appendix 4C - quarterly-VLA.AX
26/07/16PRICE SENSITIVE
VLA Change of Director's Interest Notice-VLA.AX
29/06/16
VLA Cleansing Notice-VLA.AX
28/06/16
VLA Appendix 3B-VLA.AX
28/06/16
VLA Change in substantial holding-VLA.AX
17/06/16
VLA Updated Clinical Trial Data Presented at ASCO Annual Meeting-VLA.AX
06/06/16PRICE SENSITIVE
VLA Cleansing Notice-VLA.AX
26/05/16
VLA Appendix 3B-VLA.AX
26/05/16
VLA Change of Director's Interest Notice-VLA.AX
09/05/16
VLA Viralytics Corporate Presentation May 2016-VLA.AX
04/05/16
VLA Appendix 4C - quarterly-VLA.AX
28/04/16PRICE SENSITIVE
VLA Positive Clinical Data from CAVATAK and YERVOY Combination-VLA.AX
19/04/16PRICE SENSITIVE
VLA CAVATAK Immune Activity in Tumour Micro-environment-VLA.AX
19/04/16PRICE SENSITIVE
VLA Checkpoint Combination active in Preclinical Lung, Melanoma-VLA.AX
19/04/16PRICE SENSITIVE
VLA Viralytics to Present Clinical Data at AACR Annual Meeting
17/03/16
VLA Positive CAVATAK Clinical Data Presented at EAU Congress
15/03/16PRICE SENSITIVE
VLA S&P DJ Indices Announces March Quarterly Review
11/03/16
VLA Appendix 4D Half Yearly Report and Accounts
23/02/16PRICE SENSITIVE
VLA Change of Director's Interest Notice
02/02/16
VLA Appendix 4C - quarterly
27/01/16PRICE SENSITIVE
VLA Appendix 3B - Share Purchase Plan
27/01/16
VLA Viralytics Completes $4 Million Share Purchase Plan
25/01/16
VLA Ceasing to be a substantial holder
04/01/16
VLA Change in substantial holding
23/12/15
VLA Change in substantial holding
23/12/15
VLA Appendix 3B and Cleansing Notice
21/12/15
VLA Becoming a substantial holder
21/12/15
VLA Despatch of Share Purchase Plan Offer Documents
17/12/15
VLA Viralytics Share Purchase Plan
14/12/15
VLA Cleansing Notice - Share Purchase Plan
14/12/15
VLA Additional Placement Details
14/12/15
VLA Viralytics completes $28 million Placement - SPP to follow
14/12/15PRICE SENSITIVE
VLA Trading Halt
10/12/15PRICE SENSITIVE
VLA Viralytics Receives $2.9 Million R&D Tax Incentive
09/12/15PRICE SENSITIVE
VLA Change of Director's Interest Notice x 4
20/11/15
VLA Appendix 3B
18/11/15
VLA Results of Meeting
18/11/15
VLA AGM Presentation
18/11/15
VLA Chairman's Address to Shareholders
18/11/15
VLA Positive CAVATAK Clinical Data Presented at 2015 SITC
09/11/15PRICE SENSITIVE
VLA Viralytics and Merck Collaborate in Lung and Bladder Cancer
06/11/15PRICE SENSITIVE
VLA Appendix 4C - quarterly
28/10/15PRICE SENSITIVE
VLA Notice of Annual General Meeting/Proxy Form
19/10/15
VLA Appendix 3B - Issue of Options and Performance Rights
28/09/15
VLA VLA initiates Clinical Trial of CAVATAK and PD-1 Combination
28/09/15PRICE SENSITIVE
VLA Viralytics Presents Data at European Cancer Congress
28/09/15PRICE SENSITIVE
VLA Date of Annual General Meeting
17/09/15
VLA Director and Management Options for Viralytics Leadership
15/09/15
VLA Appendix 3B
08/09/15
VLA Viralytics Annual Report and Full Year Financial Results
26/08/15
VLA Appendix 4G and Corporate Governance Statement
26/08/15
VLA Appendix 4E and Full Year Statutory Accounts
26/08/15PRICE SENSITIVE
VLA Appendix 4C - quarterly
21/07/15PRICE SENSITIVE
VLA Presentation Bioshares Biotech Summit
17/07/15
VLA Appendix 3B
29/06/15
VLA Revised Securities Trading Policy
25/06/15
VLA Becoming a substantial holder
23/06/15
VLA VLA presents on CALM and STORM at OV Conference
17/06/15
VLA Correction to Announcement - CAVATAK Presentations
16/06/15
VLA CAVATAK Presentations Potential in Bladder Cancer & Melanoma
16/06/15
VLA Investor Teleconference - CAVATAK CALM Trial Results
12/06/15
VLA VLA to Present CAVATAK Bladder and Other Results at Conf.
09/06/15
VLA Positive final results from CAVATAK Phase 2 Melanoma Trial
02/06/15PRICE SENSITIVE
VLA VLA to present final CALM Clinical Data at ASCO 2015
13/05/15
VLA Appendix 4C - quarterly
28/04/15PRICE SENSITIVE
VLA AACR Annual Meeting - Update on CALM & STORM Trials
21/04/15PRICE SENSITIVE
VLA Ceasing to be a substantial holder
15/04/15
VLA VLA to present CAVATAK clinical data at AACR Annual Meeting
18/03/15
VLA Viralytics to Present at Annual ROTH Investment Conference
09/03/15
VLA Response to Price Query Letter
27/02/15PRICE SENSITIVE
VLA Half Yearly Report and Accounts
17/02/15PRICE SENSITIVE
VLA VLA commences Clinical Trial of CAVATAK in Bladder Cancer
27/01/15PRICE SENSITIVE
VLA Appendix 4C - quarterly
22/01/15PRICE SENSITIVE
VLA Change of Director's Interest Notice
04/12/14
VLA Commencement of Checkpoint Inhibitor Combination trial
04/12/14PRICE SENSITIVE
VLA Viralytics Receives $2.5 Million R&D Tax Incentive
02/12/14PRICE SENSITIVE
VLA Correction - Change of Director's Interest Notice
28/11/14
VLA Appendix 3B - Correction
28/11/14
VLA Change of Director's Interest Notices
28/11/14
VLA Appendix 3B
28/11/14
VLA Change in substantial holding
28/11/14
VLA Results of Meeting
27/11/14
VLA Managing Director's AGM Address
27/11/14
VLA Chairman's AGM Address
27/11/14
VLA Viralytics Shareholder Newsletter Nov 2014
24/11/14
VLA Approval for CAVATAK Clinical Trial - Bladder Cancer
14/11/14PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024 The ASX finished up around 8,400 points after flirting with the 8,410 level throughout the day, clearly, in a good mood.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.